Entrada Therapeutics (TRDA) Stock: Buy, Sell, or Hold?
TRDA - Entrada Therapeutics, Inc. Common Stock
$6.80
0.38 (5.92%)
▲
5d:
-5.16%
30d:
-11.34%
90d:
+7.77%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When TRDA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: TRDA shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: TRDA shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: TRDA is currently trading at $6.80, which is considered oversold relative to its 30-day fair value range of $6.91 to $7.51.
Technical Outlook: Technically, TRDA is in a downtrend. Immediate support is located at $6.29, while resistance sits at $7.70. The stock is showing strong short-term momentum, up 5.9% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $19.00 (+179.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TRDA is in a downtrend. Immediate support is located at $6.29, while resistance sits at $7.70. The stock is showing strong short-term momentum, up 5.9% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $19.00 (+179.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$6.91 -
$7.51
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
87.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.9%)
- BULLISH: Trading 179.4% below Wall St target ($19.00)
- WARNING: Composite score 48/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$6.91 -
$7.51
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$6.29
Resistance Level
$7.70
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.26
Wall Street Target
$19.00
(+179.4%)
Revenue Growth (YoY)
-53.9%
Share & Embed Analysis
Last updated: September 12, 2026 11:09 PM ET
Data refreshes hourly during market hours. Next update: 12:09 AM
Data refreshes hourly during market hours. Next update: 12:09 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TRDA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Kory James Wentworth
SELL
2500 shares
2026-04-01
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 58 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 56 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 60 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 57 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 55 HOLD |